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Abstract: 
Background and Aims:  Prior studies assessing the yield of a second screening colonoscopy 
performed 10 years after an initial negative screening colonoscopy did not include a control 
group of persons undergoing their first screening colonoscopy during the same time interval. 
Our aim was to describe the incidence of neoplasia at a second screening colonoscopy 
(performed at least 8 years after the first colonoscopy) in average risk individuals and compare it 
with the yield of first screening examinations performed during the same time interval. 
Methods:  Review of a database of outpatient screening colonoscopies performed between 
January 2010 and December 2015 in an Atlanta private practice.  
Results: A total of 2105 average risk individuals underwent screening colonoscopy, including 
470 individuals (53.6% female; mean age 64.0 ± 3.9 years) who underwent a second screening 
examination. In those undergoing second screening, the mean interval between examinations was 
10.4 years (±1.1; range 8-15 years).  At second screening, the polyp detection rate (PDR), 
adenoma detection rate (ADR) and advanced neoplasm rate (ANR) were 44.7%, 26.6%, and 
7.4%, respectively.  Of 40 advanced neoplasms in 35 individuals, 33 (82.5%) were proximal to 
the sigmoid colon, and there were no cancers. During the same interval, 1635 individuals (49.4% 
female; mean age 52.6 ± 3.4 years) underwent their first screening colonoscopy.  The PDR, ADR 
and ANR were 53.5%, 32.2%, and 11.7%, respectively. Of 243 advanced neoplasms in 192 
individuals, 152 (62.6%) were proximal to the sigmoid colon, and there were no cancers. After 
adjustment for age, gender, body mass index, and endoscopist, PDR, ADR, and ANR were all 
lower at the second screening colonoscopies than at first-time colonoscopies (all p<0.001). 
Conclusions:  Despite being 10 years older, persons with a negative screening colonoscopy 10 
years earlier had numerically lower rates of adenomas and advanced neoplasms at their second 
screening examination compared with patients in the same practice undergoing their first 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
screening colonoscopy, and they had no cancers.  The fraction of advanced neoplasms that were 
proximal to the sigmoid was high in both first and second screenings.  These results support the 
safety of the recommended 10-year interval between colonoscopies in average risk persons with 
an initial negative examination. 
 
 
Introduction: 
Since colonoscopy was first proposed for average-risk screening in 1997 (1), the recommended 
interval between colonoscopies for average-risk persons with an initial normal examination has 
been 10 years in all guidelines.  Confidence in this recommendation has been undermined in the 
perspective of some practitioners by the numerous reports of colorectal cancer occurring after a 
colonoscopy that apparently had cleared the colon of neoplasia (2-8).  Awareness of these 
“interval” cancers likely contributes to the performance of screening colonoscopy at 5-year 
intervals by some practitioners (9).  However, despite the current detailed understanding of the 
variable detection skills of colonoscopists for both adenomas and serrated lesions (10,11), and 
the imperfect protection of colonoscopy against colorectal cancer, available evidence suggests 
that the recommended 10-year interval is safe and appropriate.  For example, the yield of 
advanced lesions and cancers is very low when colonoscopy is repeated in average-risk persons 5 
years after an initial negative examination (12,13), and a case-control study found that a negative 
screening colonoscopy provides substantial protection against colorectal cancer for at least 20 
years (14).   
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A previous single center observational study described the incidence of neoplasia at a second 
screening colonoscopy 10 years after a negative examination (15).  In that study of 378 
individuals, 38.1% had one or more conventional adenomas, and only 3.4% had an advanced 
neoplasm.   
 
In the current study we extend the observations of the yield of a second screening colonoscopy 
10 years after a negative examination.  Compared with the first study (15), the current study is 
larger, describes the yield of second screening in a U.S. private practice rather than an academic 
institution, and includes a control group of persons undergoing their first screening colonoscopy 
during the same time period and by the same colonoscopists, thereby allowing a comparison of 
the yield of first versus second screenings. 
 
Materials and Methods 
 
This was a retrospective review of colonoscopies performed at an outpatient endoscopy unit in a 
private practice in Atlanta between January 2010 and December 2015.  Eligible subjects were at 
least 50 years of age at their baseline examination, had screening listed as the indication, had a 
complete examination to the cecum with the bowel preparation listed as fair, good, or excellent 
and/or with Boston Bowel Preparation Scores of 6 to 9.  Because the data were acquired in 
Atlanta and de-identified for analysis, the Institutional Review Board at Indiana University 
waived review of the study. 
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All of the procedures in the study were performed at one ambulatory surgery center (ASC).  The 
patient population served by the ASC is approximately 15% African American, and the 
remainder of the patients are largely white.  The patients are uniformly insured (either private 
insurance and/or Medicare).  The database was created retrospectively by technical support 
personnel in Atlanta for quality assessments.   Provation (Provation Medical, Minneapolis, 
Minn) was introduced in the ASC in 1999 as the endoscopic report generating system for the 
center.  Provation was searched by its key word search function to identify screening procedures.  
Endoscopist, patient demographics, and polyp findings were determined from Provation reports.  
When a patient was identified, the patient’s chart was reviewed to identify polyp pathology. The 
nurse’s notes documented the patient’s height and weight.  These were entered into bmi-
calculator.net to determine body mass index (BMI).  The de-identified database was coded for 
endoscopist and sent to Indianapolis for analysis.  
 
Individuals undergoing a second screening examination during the study period had undergone a 
baseline screening examination in the same practice between January 2002 and December 2007 
and had either no colorectal polyps or had only hyperplastic polyps <10 mm in size in the rectum 
or sigmoid colon identified during the baseline colonoscopy. The second examination occurred a 
minimum of 8 years after the first examination.  The same 11 gastroenterologists performed both 
the first and the second screenings. 
 
Conventional adenomas included tubular, tubulovillous and villous adenomas. Serrated class 
lesions included hyperplastic polyps, sessile serrated polyps (SSP; synonymous with sessile 
serrated adenoma), and traditional serrated adenomas (TSA).  Advanced neoplasms were defined 
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as adenomas with villous elements, high-grade dysplasia, or size ≥10 mm, SSPs ≥10 mm in size 
or with cytological dysplasia and TSAs ≥10 mm in size.  The database for the study recorded 
age, gender, polyp findings (size, location, and pathology), and body mass index (BMI).  
 
Statistical Methods:  
Chi-squared tests were used to compare polyp, adenoma, and advanced neoplasm rates between 
the groups.  Wilcoxon rank sum t-test was done to compare adenomas per colonoscopy between 
the groups.  Multivariable logistic and linear regression was used to determine if the groups 
differences persisted after adjusting for age, BMI, and endoscopist.  Because the number of 
adenomas per colonoscopy is highly positively skewed, the square root of number of 
colonoscopies was used in the multivariable linear regression.  Although the square root is still 
positively skewed, the residuals were examined and were approximately normally distributed. 
 
Results 
A total of 2105 individuals underwent screening colonoscopy during the study interval, 
of which 470 individuals underwent a second screening colonoscopy at least 8 years after their 
initial examination and 1635 individuals underwent their first screening examination. Of the 470 
individuals undergoing a second screening, 440 had no polyps at their baseline examination and 
30 had only distal colon (rectum and/or sigmoid) hyperplastic polyps <10 mm in size. 
Second screening group 
The second screening group was 53.6% female, had mean (SD) age 64.0 (3.9) (range: 59-
80) years.  The mean (SD) BMI was 26.4 (4.4). The mean (SD) interval between examinations 
was 10.4 (1.1) (range: 8.0-15.0) years. (Table 1).  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
There were 35 individuals (17 females) with 40 advanced neoplasms at the second 
examination, of which 33 (82.5%) were proximal to the sigmoid colon. The overall polyp 
detection rate (PDR), adenoma detection rate (ADR), adenomas per colonoscopy (APC), and 
advanced neoplasm detection rate (ANR) at the second examination were 44.7%, 26.6%, 0.44 
and 7.4%, respectively. ADR was 25.7% in subjects with no baseline polyps and 40.0% in 
patients with distal colon hyperplastic polyps at the baseline colonoscopy (Table 2).  No cancers 
were identified.   Among 363 patients with at least 10 years between examinations, the PDR, 
ADR, APC and ANR were 46.6%, 27.8%, 0.47, and 8.0%, respectively.  
 Multi-variable logistic regression showed that higher BMI was associated with a higher 
risk of adenoma at a second screening colonoscopy (odds ratio, 1.44; 95% CI, 1.12 - 1.84) for 
each 5-point increase in BMI (Table 3). 
  
Initial screening group 
Among 1635 subjects who underwent initial screening colonoscopy (the screening 
colonoscopy control group) during the study period, the mean (SD) age was 52.6 (3.4) (range 50-
81) years and 808 (49.4%) were women. The mean (SD) BMI was 26.9 (5.0) (Table 1). The 
PDR, ADR, APC, and ANR were 53.5%, 32.2%, 0.54, and 11.7%, respectively (Table 2). There 
were 192 individuals (85 females) with 243 advanced neoplasms of which 152 (62.6%) were 
proximal to the sigmoid.  There were no cancers. 
 On multi-variable analysis BMI was significantly associated with the presence of 
adenomas. For each 5 point increase in BMI in the first screening colonoscopy group, the odds 
for adenoma increased by 1.26 (95% CI, 1.13 - 1.41).  Each 5-point increase in BMI was 
associated with a 1.20 increased risk of advanced neoplasm (95% CI, 1.03 - 1.39) (Table 3). 
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Group comparisons 
 Univariate analysis of the yield of polyps, adenomas, advanced neoplasms, and adenomas 
per colonoscopy indicated that each of these endpoints was higher in the control group 
undergoing first-time screening compared with patients undergoing second screening. These 
differences all persisted after logistic regression to control for the effects of gender, age, BMI 
and endoscopist (10 of the 12 endoscopists with >50 procedures were included in the analysis) 
(Table 4).   
We qualitatively examined multiple subpopulations of second screening subjects in an 
attempt to identify a subgroup with either zero or an extremely low risk of advanced neoplasia at 
the second colonoscopy.  Although age, gender, and BMI were all associated with neoplasia, we 
did not identify any such subgroup (data not shown). 
Discussion 
In this report we demonstrate that the yield of a second screening colonoscopy in 470 persons 
who had a negative screening colonoscopy at least 8 years and an average of 10.4 years earlier 
was 0% for cancer and lower for adenomas and advanced neoplasms than first-time screening 
colonoscopies.  This was true even though patients were 10 years older than first-time screening 
patients, and increasing age is strongly associated with colorectal adenomas and cancer.  Thus, 
patients with a negative colonoscopy appear to be selected for a lower risk of colorectal 
neoplasia.  Our results indicate that the current recommendation for colonoscopy every 10 years 
in persons with initial negative examinations is safe and appropriate.  For both first and second 
screening colonoscopies the majority of advanced lesions were in the proximal colon, increasing 
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the rationale for screening by colonoscopy.  This finding was also observed for second screening 
examinations in the prior published study (15). 
 
 Our data suggest that females with normal BMI are a candidate group to evaluate in larger 
studies of second screening examinations because they might be candidates for colonoscopy 
examinations at intervals >10 years after an initial negative examination.  Additional study is 
needed to evaluate this suggestion. 
The main result in our study is that the observed incidence of adenomas and advanced neoplasms 
at a second screening 10 years after a negative baseline examination is lower than the yield of 
first-time screening colonoscopy, even though patients are 10 years older.  A previous single 
center report in 378 persons undergoing screening colonoscopy after an initial negative 
examination found an incidence of advanced neoplasms of 3.4%, but did not include a control 
group of patients undergoing initial screening colonoscopy during the same time interval (15). A 
study from the Clinical Outcomes Research Initiative database reported that the incidence of 
polyps >9 mm at 7 to <10 years after a negative initial baseline screening colonoscopy was 
4.4%.  However, 42.3% of the population had a family history of colorectal cancer or polyps, 
13.6% initially underwent colonoscopy for a positive fecal blood test, 36.5% had symptoms or 
positive screening tests as the indication for the second colonoscopy, and there was no control 
group undergoing first-time screening in the same time period (16).  A small study of patients 
with a negative index colonoscopy found that the rate of advanced lesions in patients undergoing 
repeat colonoscopy at 6 to 10 years was 3.6%, which was not different than the incidence of 7% 
for repeat colonoscopies at 5 years (p=0.15).   However, no control group of patients undergoing 
first-time screening colonoscopy in the same time interval was included (17). 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
This study has several limitations.  First, the number of persons undergoing a second screening 
colonoscopy was lower than those undergoing a first screening colonoscopy, suggesting that 
selection bias might result in important differences between the two groups of patients.  Thus, 
patients presenting for a second colonoscopy might lead a healthier lifestyle, and generally 
interact more frequently with the health care system.  However, in screening studies, patient age, 
gender, smoking status, and obesity are the main determinants of adenoma prevalence (18). 
Willingness to undergo screening has never been shown to be a predictor of neoplasia 
prevalence.  Second, the study is underpowered to evaluate some relevant outcomes, particularly 
colorectal cancer, and to evaluate predictors of advanced lesions in a multivariable regression. 
The overall lower rates of adenomas and advanced lesions at the second examination compared 
with the first screening colonoscopy, despite the older age at the second screen, seems to be the 
relevant result of the study.  Increasing age has always been a powerful predictor of colorectal 
neoplasia in screening populations.  The low rate of neoplasia in the second screening group in 
this study, despite their older age compared with first-time screenees, is evidence of the powerful 
negative predictive value of a normal colonoscopy. Additional studies to evaluate specific 
predictors of advanced lesions at a second screening colonoscopy will be needed. Third, as a 
single center study, generalizability of the results is uncertain. Fourth, we did not have data on a 
number of factors that might predict the incidence of precancerous lesions at a second screening 
colonoscopy, including use of aspirin and non-steroidal anti-inflammatory drugs, family history, 
smoking status, bowel preparation scores at the baseline colonoscopy, or comorbidities such as 
diabetes. Finally, we did not have complete follow-up of the initial cohort, and patients may have 
developed cancer detected at earlier symptomatic examinations at the study ASC at outside 
centers, or had second screening colonoscopies at other centers.  This does not negate the 
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important observation that patients remaining asymptomatic 10 years after an initial negative 
screening colonoscopy have a lower rate of colorectal neoplasia than first-time screenees who 
are 10 years younger. 
In conclusion, our study demonstrates that the yield of a second screening colonoscopy 10 years 
after an initial negative examination is lower than the yield of first-time screening, and supports 
the current recommendation of screening colonoscopy at 10-year intervals.   
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Table 1: Patient demographics 
  
  
Second screen group 
Initial screening 
group 
Subjects 
without 
polyps at 
baseline 
exam 
Subjects with 
distal 
hyperplastic 
polyps at 
baseline exam 
Total 
n=440 n=30 n=470 n=1635 
 n (%) n (%) n (%) n (%) 
Sex     
Male 205 (46.6) 13 (43.3) 218 (46.4) 827 (50.6) 
Female 235 (53.4) 17 (56.7) 252 (53.6) 808 (49.4) 
 
Mean (SD) 
Range 
Mean (SD) 
Range 
Mean (SD) 
Range 
Mean (SD) 
Range 
Age at initial colonoscopy 53.5(3.6) 50-67 
54.3(4.1) 
50-66 
53.5 (3.7) 
50-67 
52.6 (3.9) 
50-81 
Age at second colonoscopy 63.9(3.8) 59-80 
64.3(4.3) 
59-76 
64.0 (3.9) 
59-80 - 
Interval between colonoscopies (years)  10.5 (1.0) 8.0-15.0 
10.0 (1.1) 
8.0-12.6 
10.4 (1.1) 
8.0-15.0 - 
BMI 26.3 (2.2) 16.9-43.5 
27.3 (4.5) 
17.0-36.9 
26.4 (4.4) 
16.9-43.5 
26.9 (5.0) 
16.6-57.5 
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Table 2: Yield of screening colonoscopy in the first and second screening groups: number of 
patients with at least one lesion of different types and total number of lesions detected according 
to histology 
  
  
 
 
 
 
 
Number of patients 
Second screen group 
Initial screening 
group 
Subjects 
without polyps 
at baseline 
exam 
Subjects with 
distal 
hyperplastic 
polyps at 
baseline exam 
Total 
n=440  n=30  n=470 n=1635 
Yield by patient n (%)* n (%) n (%) n (%) 
Patients with ≥1 polyp 192 (43.6) 18 (60.0) 210 (44.7) 875 (53.5) 
Patients with ≥1 adenoma 113 (25.7) 12 (40.0) 125 (26.6) 526 (32.2) 
Patients with ≥1 advanced neoplasm 34 (7.7) 1 (2.9) 35 (7.4) 192 (11.7) 
Males with ≥1 adenoma  (n=218) 65 (31.7) 6 (46.2) 71 (32.6) 309 (37.4) 
Females with ≥1 adenoma (n=252) 48 (20.4) 6 (35.3) 54 (21.4) 217 (26.9) 
Total number of lesions detected n=334 n=33 n=367 n=1718 
Histology of lesions detected n (%)** n (%) n (%) n (%) 
Tubular adenoma 185 (55.4) 20 (60.6) 205 (55.9) 839 (48.8) 
Tubulovillous adenoma 2 (0.6) 0 (0.0) 2 (0.5) 38 (2.2) 
Hyperplastic polyp 66 (19.8) 9 (27.3) 75 (20.4) 387 (22.5) 
Benign mucosa 31 (9.3) 2 (6.1) 33 (9.0) 211 (12.3) 
Sessile serrated polyp 46 (13.8) 2 (6.1) 48 (13.1) 218 (12.7) 
Other  polyp 4 (1.2) 0 (0.0) 4 (1.1) 14 (0.8) 
Traditional serrated adenoma 0 (0.0) 0 (0.0) 0 (0.0) 11 (0.6) 
• * number of patients (%) 
• ** number of lesions with designated pathology (% of all lesions detected with 
designated pathology) 
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Table 3: Within group multivariable associations with conventional adenoma and advanced 
neoplasm  
 2nd Screening Group – Conventional 
Adenoma 
 OR 95% CI P value 
Age (10-year increase) 2.52 (1.44 - 4.42) 0.001 
Sex (M vs F) 1.79 (1.12 - 2.88) 0.015 
BMI (5-point increase) 1.44 (1.12 - 1.84) 0.005 
 Initial Screening Group – Conventional 
Adenoma 
Age (10-year increase) 1.09 (1.06 - 1.13) <0.001 
Sex (M vs F) 1.58 (1.26 - 1.98) <0.001 
BMI (5-point increase) 1.26 (1.13 - 1.41) <0.001 
 Initial Screening Group – Advanced 
Neoplasm 
Age (10-year increase) 1.10 (1.06 - 1.14) <0.001 
Sex (M vs F) 1.29 (0.93 - 1.78) 0.127 
BMI (5-point increase) 1.20 (1.03 - 1.39) 0.020 
 
M: male 
F: female 
BMI: Body Mass Index 
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Table 4: Between group comparisons of lesion yields in patients undergoing second versus initial 
screening colonoscopies 
 Second 
screening 
patients 
(n=470) 
Initial 
screening 
patients 
(n= 1635) 
OR (95% CI) 
Initial vs 2nd 
Univariate 
group 
P value 
Multivariable 
group 
P value 
PDR 44.7% 53.5% 2.99 (2.00 - 4.45) <0.001 <0.001 
ADR 26.6% 32.2% 3.09 (2.07 - 4.63) 0.021 <0.001 
APC 0.44 0.54 - 0.024 <0.001 
ANR 7.4% 11.7% 4.55 (2.61 - 
7.91) 
0.008 
<0.001 
 
PDR: polyp detection rate (% of patients with ≥ 1 polyp) 
ADR: adenoma detection rate (% of patients with ≥ 1 adenoma) 
APC: adenomas per colonoscopy 
ANR: advanced neoplasm rate (% of patients with ≥ 1 advanced neoplasm) 
 
 
 
 
 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
PDR Polyp Detection Rate 
ADR Adenoma Detection Rate 
ANR Advanced Neoplasm Rate 
SSP Sessile Serrated Polyps 
TSA Traditional Serrated Adenoma 
BMI Body Mass Index 
APC Adenomas per Colonoscopy 
SD Standard Deviation 
CI Confidence Interval 
OR Odds Ratio 
 
